ReGenHeart | Clinical development and proof of principle testing of new regenerative VEGF-D therapy for cost-effective treatment of refractory angina A phase II randomized, double-blinded, placebo-controlled study

Summary
Chronic angina pectoris is a debilitating chronic disease, a subgroup of these patients suffers from refractory angina which unfortunately can’t be controlled by medical therapy (angioplasty or surgery). Refractory angina is a substantial burden on the individual and healthcare system, in Europe there are 100,000 new cases per year, annual mortality of these patients is relatively low (
Resources Show all and search (4)
Unfold all
/
Fold all
More information & hyperlinks
Web resources: https://cordis.europa.eu/project/id/731532
Start date: 01-01-2017
End date: 31-12-2022
Total budget - Public funding: 5 934 088,00 Euro - 5 934 086,00 Euro
Cordis data

Original description

Chronic angina pectoris is a debilitating chronic disease, a subgroup of these patients suffers from refractory angina which unfortunately can’t be controlled by medical therapy (angioplasty or surgery). Refractory angina is a substantial burden on the individual and healthcare system, in Europe there are 100,000 new cases per year, annual mortality of these patients is relatively low (

Status

CLOSED

Call topic

SC1-PM-11-2016-2017

Update Date

26-10-2022
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.3. Treating and managing disease
H2020-EU.3.1.3.0. Cross-cutting call topics
H2020-SC1-2016-RTD
SC1-PM-11-2016-2017 Clinical research on regenerative medicine
H2020-SC1-2017-Single-Stage-RTD
SC1-PM-11-2016-2017 Clinical research on regenerative medicine
Search
Search on Google
Search on Bing
Search on DuckDuckGo
Organisations
Show all (11)
Powered by Chris Decubber BV